Advancing Education on Biosimilars Act of 2021
USA117th CongressS-164| Senate
| Updated: 4/23/2021
Margaret Wood Hassan
Democratic Senator
New Hampshire
Cosponsors (1)
Health, Education, Labor, and Pensions Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Advancing Education on Biosimilars Act of 2021 This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.) The FDA may also maintain and operate a website to provide educational materials about biological products.
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(text: CR S1021)
Passed Senate without amendment by Unanimous Consent. (text: CR S1021)
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.(consideration: CR S1021)
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S1021)
Message on Senate action sent to the House.
Received in the House.
Held at the desk.
Mr. Pallone moved to suspend the rules and pass the bill.
Considered under suspension of the rules. (consideration: CR H1754-1755)
DEBATE - The House proceeded with forty minutes of debate on S. 164.
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Considered as unfinished business. (consideration: CR H1783-1784)
On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 8 (Roll no. 101). (text: CR H1754)
View VoteMotion to reconsider laid on the table Agreed to without objection.
Presented to President.
Signed by President.
Became Public Law No: 117-8.
Health
Drug safety, medical device, and laboratory regulationGovernment information and archivesHealth personnelLicensing and registrationsMedical educationPrescription drugs
Advancing Education on Biosimilars Act of 2021
USA117th CongressS-164| Senate
| Updated: 4/23/2021
Advancing Education on Biosimilars Act of 2021 This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.) The FDA may also maintain and operate a website to provide educational materials about biological products.
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(text: CR S1021)
Passed Senate without amendment by Unanimous Consent. (text: CR S1021)
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.(consideration: CR S1021)
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S1021)
Message on Senate action sent to the House.
Received in the House.
Held at the desk.
Mr. Pallone moved to suspend the rules and pass the bill.
Considered under suspension of the rules. (consideration: CR H1754-1755)
DEBATE - The House proceeded with forty minutes of debate on S. 164.
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Considered as unfinished business. (consideration: CR H1783-1784)
On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 8 (Roll no. 101). (text: CR H1754)
View VoteMotion to reconsider laid on the table Agreed to without objection.
Presented to President.
Signed by President.
Became Public Law No: 117-8.
Margaret Wood Hassan
Democratic Senator
New Hampshire
Cosponsors (1)
Health, Education, Labor, and Pensions Committee
Health
Related Bills
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Drug safety, medical device, and laboratory regulationGovernment information and archivesHealth personnelLicensing and registrationsMedical educationPrescription drugs